Twist Bioscience Co. (NASDAQ:TWST) Shares Bought by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD boosted its stake in shares of Twist Bioscience Co. (NASDAQ:TWST) by 15.5% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 41,401 shares of the company’s stock after purchasing an additional 5,554 shares during the period. Price T Rowe Associates Inc. MD owned approximately 0.07% of Twist Bioscience worth $1,924,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of TWST. Stifel Financial Corp grew its holdings in Twist Bioscience by 19.6% during the fourth quarter. Stifel Financial Corp now owns 8,331 shares of the company’s stock worth $387,000 after acquiring an additional 1,364 shares during the period. Tower Research Capital LLC TRC lifted its stake in shares of Twist Bioscience by 30.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,059 shares of the company’s stock valued at $282,000 after purchasing an additional 1,414 shares during the period. MetLife Investment Management LLC boosted its holdings in Twist Bioscience by 6.0% during the fourth quarter. MetLife Investment Management LLC now owns 35,222 shares of the company’s stock worth $1,637,000 after buying an additional 1,987 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in Twist Bioscience during the fourth quarter valued at $2,272,000. Finally, Marshall Wace LLP increased its holdings in Twist Bioscience by 15,927.8% in the fourth quarter. Marshall Wace LLP now owns 846,107 shares of the company’s stock valued at $39,319,000 after buying an additional 840,828 shares in the last quarter.

Insider Transactions at Twist Bioscience

In related news, insider Dennis Cho sold 689 shares of the firm’s stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $37.65, for a total transaction of $25,940.85. Following the completion of the sale, the insider now directly owns 110,849 shares in the company, valued at approximately $4,173,464.85. This trade represents a 0.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert Chess sold 2,940 shares of the business’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $53.13, for a total transaction of $156,202.20. Following the completion of the transaction, the director now owns 18,173 shares in the company, valued at $965,531.49. The trade was a 13.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 21,931 shares of company stock worth $898,856 in the last quarter. Company insiders own 3.01% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on TWST. The Goldman Sachs Group cut their price target on Twist Bioscience from $55.00 to $48.00 and set a “buy” rating for the company in a research note on Tuesday. JPMorgan Chase & Co. decreased their target price on Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating on the stock in a research report on Tuesday. Barclays cut their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating for the company in a report on Thursday, April 10th. Guggenheim reaffirmed a “buy” rating and set a $50.00 price objective on shares of Twist Bioscience in a report on Tuesday. Finally, Robert W. Baird cut their target price on shares of Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating for the company in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $50.40.

Twist Bioscience Stock Up 0.1 %

Shares of NASDAQ TWST opened at $32.78 on Thursday. The stock has a market cap of $1.96 billion, a PE ratio of -9.70 and a beta of 2.54. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a 12-month low of $31.56 and a 12-month high of $60.90. The company has a 50-day moving average of $38.90 and a 200 day moving average of $43.82.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company had revenue of $92.79 million during the quarter, compared to analysts’ expectations of $92.00 million. As a group, sell-side analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.